Too Few Women Treated for Vulvovaginal Atrophy, Dyspareunia Too Few Women Treated for Vulvovaginal Atrophy, Dyspareunia

Although cost is a major barrier to prescription therapy for vulvovaginal atrophy and painful intercourse, the reticence of physicians to discuss sexuality might also be an issue, new research shows.Medscape Medical News

Source: Medscape Medical News Headlines - October 31, 2017 Category: Consumer Health News Tags: Ob/Gyn & Women ' s Health News Source Type: news